Health

FDA Approves Pfizer’s Second Vaccine Booster, Moderna vs. COVID-19 for Adults Over 50

(CNN / KDKA) – The US Food and Drug Administration has expanded the emergency use of Pfizer and Moderna Covid-19 to allow adults 50 years of age and older to receive a second booster dose four months after the first booster dose. Covid-19 vaccine.

This move expands the availability of additional boosters for healthy seniors. Previously, the FDA allowed second vaccinations for anyone 12 years of age and older who had a severe immune deficiency starting four months after their first revaccination.

“Although public health facilities tend to want unequivocal recommendations because they are easier to announce, deploy, or promote,” said Infectious Diseases expert Amesh Adalya. “But that’s not where the science is. It actually ends up, in the end, losing public trust because they know it’s not the same for people with weakened immune systems and those whose immunity is not compromised.”

UPMC Medical Director Dr Graham Snyder said people with weakened immune systems had access to the booster. Now is the time for everyone else in the group.

“I fully expect that the vaccine schedule will be revised over time as we look for better and better ways to prepare a vaccine for our immune system. So be prepared for more change in the coming months, ”he said.

The U.S. Centers for Disease Control and Prevention is expected to issue a so-called permit recommendation – a statement that in this age group, vaccinations can be used for those who want to. However, the agency is not expected to officially recommend filming.

There is a general scientific consensus that third doses help boost immunity against severe disease from the virus that causes Covid-19. But science is far from dwelling on when and when even fourth doses may be needed, as vaccines still provide a high degree of protection against hospitalization and death of Covid-19, even when protection against the disease is weakening.

Much of the evidence for the safety and effectiveness of the second vaccine comes from Israel, which since late January has recommended a fourth dose of the coronavirus vaccine for adults 18 years of age and older.

In a large study involving more than half a million adults over the age of 60 in those who received a second booster, or fourth dose of the Covid-19 vaccine, the probability of death during the Omicron wave was 78% lower than those who received a third shot at least four months earlier. But the death toll was relatively low in both groups. After 40 days of follow-up, 232 deaths were recorded from nearly 234,000 people who received only three doses of Pfizer-BioNTech vaccine, compared with 92 deaths from 328,000 people.

A smaller study of health professionals that included young people found that the fourth boosters were safe and restored antibodies to the same levels that were achieved after the third dose. But the fourth doses were only moderately effective – about 30 to 40% – in preventing the disease. And most of the sick workers still had a high viral load, it was believed that they were able to transmit the infection to others.

Additional studies in the UK show that the gain of antibodies from a booster dose weakens very quickly, within a few weeks. Therefore, some experts believe that given the available resources and reduced appetite to continue receiving more and more stimulants the United States should wait until there is a clear danger of a new wave of infections to release the fourth dose.

UPMC plans to sort out in the next few days to prepare for the introduction of these second boosters. Allegheny Health Network has stated that people will be able to register through My Chart.

(TM and © Copyright, 2022 CBS Broadcasting Inc. All rights reserved. This material may not be published, broadcast, rewritten or distributed. CNN contributed to this report.)

https://www.cbsnews.com/pittsburgh/news/fda-pfizer-moderna-covid-booster-shot-authorizations/

Back to top button